Chidamide combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four drugs (chidamide, a PD-1 inhibitor, bevacizumab, and XELOX chemotherapy) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have stage 4 colorectal cancer that cannot be removed by surgery or has come back and spread.
- You must not have had any previous chemotherapy or other systemic treatment for metastatic colorectal cancer.
- If you had chemotherapy before surgery to prevent cancer from coming back, it must have been more than 12 months ago.
- You must be able to do most of your daily activities without help (ECOG 0 or 1).
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This study is looking at how well a combination of medications works for people with advanced colorectal cancer that is microsatellite stable (MSS). The medications include chidamide, a PD-(L)1 inhibitor (a type of immunotherapy), and anti-angiogenic therapy (a treatment that blocks blood vessel growth to tumors).
This study tests a combination of three drugs — Chidamide (a pill), an immunotherapy (PD-1/PD-L1 antibody), and anti-angiogenic agents (which block blood vessel growth to tumors) — for people with advanced colorectal cancer that has spread. The goal is to see how well they work together in real-world patients.
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.